Efficacy - Kesimpta
Safety Profile
The most commonly reported adverse reactions were upper respiratory tract infection (18.9%), headache (18.3%) and diarrhoea (11.0%). The most commonly reported serious adverse reaction was urinary tract infection (1.2%) 1,4 .Twitter Linkedin Facebook Pinterest Google plusClinical efficacy & safety
The efficacy and safety 5 of iptacopan in adult patients with PNH were evaluated in two multicentre, open-label, 24-week phase III studies: an active comparator-controlled study (...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action (MoA)
Mechanism of Action (MoA)¹
Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway of the complement cascade. Inhibition of FB in the...
Twitter Linkedin Facebook Pinterest Google plusDosing
Dosing¹
Posology & Method of AdministrationThe recommended dose is 200 mg taken orally twice daily.
Healthcare professionals should advise patients with PNH about the...
Twitter Linkedin Facebook Pinterest Google plusReimbursement
Unmet Need
Controlled Access
Vaccination
